Spanish Association of Paediatrics
Update of recommendations on the use of palivizumab as prophylaxis in RSV infections
Actualización de las recomendaciones de la Sociedad Española de Neonatología para la utilización del palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial
Servicio de Neonatología, Hospital Clínic, Facultad de Medicina, Barcelona, Spain
Read
7634
Timeswas read the article
2579
Total PDF
5055
Total HTML
Share statistics
array:22 [ "pii" => "S234128791500037X" "issn" => "23412879" "doi" => "10.1016/j.anpede.2014.10.007" "estado" => "S300" "fechaPublicacion" => "2015-03-01" "aid" => "1738" "copyright" => "Asociación Española de Pediatría" "copyrightAnyo" => "2014" "documento" => "article" "subdocumento" => "fla" "cita" => "An Pediatr (Barc). 2015;82:199.e1-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2498 "formatos" => array:3 [ "EPUB" => 145 "HTML" => 1803 "PDF" => 550 ] ] "Traduccion" => array:1 [ "es" => array:18 [ "pii" => "S1695403314004615" "issn" => "16954033" "doi" => "10.1016/j.anpedi.2014.10.004" "estado" => "S300" "fechaPublicacion" => "2015-03-01" "aid" => "1738" "copyright" => "Asociación Española de Pediatría" "documento" => "article" "subdocumento" => "fla" "cita" => "An Pediatr (Barc). 2015;82:199.e1-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 13594 "formatos" => array:3 [ "EPUB" => 145 "HTML" => 11109 "PDF" => 2340 ] ] "es" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">ASOCIACIÓN ESPAÑOLA DE PEDIATRÍA</span>" "titulo" => "Actualización de las recomendaciones de la Sociedad Española de Neonatología para la utilización del palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "199.e1" "paginaFinal" => "199.e2" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Update of recommendations on the use of palivizumab as prophylaxis in RSV infections" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J. Figueras Aloy, X. Carbonell Estrany" "autores" => array:3 [ 0 => array:2 [ "nombre" => "J." "apellidos" => "Figueras Aloy" ] 1 => array:2 [ "nombre" => "X." "apellidos" => "Carbonell Estrany" ] 2 => array:1 [ "colaborador" => "Comité de Estándares de la SENeo" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S234128791500037X" "doi" => "10.1016/j.anpede.2014.10.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S234128791500037X?idApp=UINPBA00005H" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403314004615?idApp=UINPBA00005H" "url" => "/16954033/0000008200000003/v2_201502230153/S1695403314004615/v2_201502230153/es/main.assets" ] ] "itemAnterior" => array:18 [ "pii" => "S2341287915000332" "issn" => "23412879" "doi" => "10.1016/j.anpede.2014.09.004" "estado" => "S300" "fechaPublicacion" => "2015-03-01" "aid" => "1720" "copyright" => "Asociación Española de Pediatría" "documento" => "article" "subdocumento" => "fla" "cita" => "An Pediatr (Barc). 2015;82:198.e1-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 5379 "formatos" => array:3 [ "EPUB" => 195 "HTML" => 4626 "PDF" => 558 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Spanish Association of Paediatrics</span>" "titulo" => "Vaccination against meningococcal B disease. Public statement of the Advisory Committee on Vaccines of the Spanish Association of Paediatrics (CAV-AEP)" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "198.e1" "paginaFinal" => "198.e9" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Vacunación frente al meningococo B. Posicionamiento del Comité Asesor de Vacunas de la Asociación Española de Pediatría" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "D. Moreno-Pérez, F.J. Álvarez García, J. Arístegui Fernández, M.J. Cilleruelo Ortega, J.M. Corretger Rauet, N. García Sánchez, A. Hernández Merino, T. Hernández-Sampelayo Matos, M. Merino Moína, L. Ortigosa del Castillo, J. Ruiz-Contreras" "autores" => array:12 [ 0 => array:2 [ "nombre" => "D." "apellidos" => "Moreno-Pérez" ] 1 => array:2 [ "nombre" => "F.J." "apellidos" => "Álvarez García" ] 2 => array:2 [ "nombre" => "J." "apellidos" => "Arístegui Fernández" ] 3 => array:2 [ "nombre" => "M.J." "apellidos" => "Cilleruelo Ortega" ] 4 => array:2 [ "nombre" => "J.M." "apellidos" => "Corretger Rauet" ] 5 => array:2 [ "nombre" => "N." "apellidos" => "García Sánchez" ] 6 => array:2 [ "nombre" => "A." "apellidos" => "Hernández Merino" ] 7 => array:2 [ "nombre" => "T." "apellidos" => "Hernández-Sampelayo Matos" ] 8 => array:2 [ "nombre" => "M." "apellidos" => "Merino Moína" ] 9 => array:2 [ "nombre" => "L." "apellidos" => "Ortigosa del Castillo" ] 10 => array:2 [ "nombre" => "J." "apellidos" => "Ruiz-Contreras" ] 11 => array:1 [ "colaborador" => "on behalf of the Comité Asesor de Vacunas de la Asociación Española de Pediatría" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1695403314004287" "doi" => "10.1016/j.anpedi.2014.09.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403314004287?idApp=UINPBA00005H" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287915000332?idApp=UINPBA00005H" "url" => "/23412879/0000008200000003/v2_201504151313/S2341287915000332/v2_201504151313/en/main.assets" ] "en" => array:19 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Spanish Association of Paediatrics</span>" "titulo" => "Update of recommendations on the use of palivizumab as prophylaxis in RSV infections" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "199.e1" "paginaFinal" => "199.e2" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "J. Figueras Aloy, X. Carbonell Estrany" "autores" => array:3 [ 0 => array:4 [ "nombre" => "J." "apellidos" => "Figueras Aloy" "email" => array:1 [ 0 => "jfiguer@clinic.ub.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "X." "apellidos" => "Carbonell Estrany" ] 2 => array:2 [ "colaborador" => "Comité de Estándares de la SENeo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">◊</span>" "identificador" => "fn1" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Servicio de Neonatología, Hospital Clínic, Facultad de Medicina, Barcelona, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Actualización de las recomendaciones de la Sociedad Española de Neonatología para la utilización del palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">The recent recommendations of the American Academy of Pediatrics (AAP) regarding palivizumab prophylaxis for children at risk to prevent serious respiratory syncytial virus (RSV) infections and hospitalisation due to these infections<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">1</span></a> oblige us to consider updating the current Recommendations of the Spanish Society of Neonatology (SENeo).<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">2,3</span></a> An analysis of the AAP document does not provide new scientific evidence that would justify modifying the SENeo's current recommendations. In the United States palivizumab is appreciably more expensive than in Spain and the financial aspects may have influenced the AAP's decision. However, it should not be forgotten that one way of reducing the cost of a drug is to administer it properly and sensibly, and in this respect there is room for improvement in palivizumab prophylaxis for Spanish infants born prematurely. Several issues need to be highlighted:<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">–</span><p id="par0010" class="elsevierStylePara elsevierViewall">In preterm infants with no bronchopulmonary dysplasia (BPD) or congenital heart disease and with a gestational age ≤28 weeks and 6 days, prescribing palivizumab in the first 12 months of life could mean repeating the complete course (5 doses), in the next season, in high-weight infants aged over 9 months. This second course could be advised against, which would lead to a substantial saving in resources, prescribing it only to those under 9 months. If the start of the RSV season is taken as 15 October, it will include those born from 15 January inclusive.</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">–</span><p id="par0015" class="elsevierStylePara elsevierViewall">The limit of 35 weeks 0 days for the moderately preterm group is liable to cause confusion, since the number of days is sometimes not known and all 35-week preterm infants are included. It seems more reasonable to include those of up to 34 weeks and 6 days, which would exclude all 35-week preterms from the recommendations. Avoiding this overtreatment would also reduce the cost of prophylaxis. It should be remembered that out of the group of preterms with a gestational age of between 32 weeks 0 days and 34 weeks 6 days the only ones treated, exceptionally, would be those that met the two main criteria: age below 10 weeks at the start of the season (born from 6 August onwards inclusive) and with at least one sibling attending school or nursery school. This subgroup accounts for approximately 18% of the total of these preterm infants.</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">–</span><p id="par0020" class="elsevierStylePara elsevierViewall">The intermediate gestational age group, between 29 weeks 0 days and 31 weeks 6 days (instead of 32 weeks 0 days, for the same reason already put forward above), would be treated if their age at the start of the season was less than 6 months (born from 15 April onwards inclusive).</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">–</span><p id="par0025" class="elsevierStylePara elsevierViewall">Neonates with congenital heart disease and with persistent haemodynamic disturbance or BPD requiring treatment in the past 12 months should be treated for a second year.</p></li></ul></p><p id="par0030" class="elsevierStylePara elsevierViewall">For prophylaxis of respiratory infections in infants and small children, including those due to RSV, the importance of hygienic measures, especially proper handwashing, should not be forgotten. The conjunction of such measures and appropriate administration of palivizumab will make it possible to reduce the health care overload (in hospital and outpatient services) and the stress for families caused by an RSV infection in children whose age and history make them vulnerable.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conflicts of interest</span><p id="par0035" class="elsevierStylePara elsevierViewall">The authors have no conflicts of interest to declare.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:6 [ 0 => array:3 [ "identificador" => "xres476156" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec498188" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres476157" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec498189" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Conflicts of interest" ] 5 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2014-09-22" "fechaAceptado" => "2014-10-02" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec498188" "palabras" => array:5 [ 0 => "Bronchiolitis" 1 => "Palivizumab" 2 => "Preterm infants" 3 => "Prevention" 4 => "Respiratory syncytial virus" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec498189" "palabras" => array:5 [ 0 => "Bronquiolitis" 1 => "Palivizumab" 2 => "Prematuros" 3 => "Prevención" 4 => "Virus respiratorio sincitial" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">The Standards Committee of the Spanish Neonatology Society (SENeo) considers that the new document from the American Academy of Pediatrics, including recommendations for palivizumab use to prevent serious infections produced by the Respiratory Syncytial Virus (RSV), provides no new scientific evidence which would justify the modification of the current recommendations of the SENeo. However, some adjustments to the criteria of the existing recommendations are proposed to reduce the cost of the drug by its correct and judicious management.</p></span>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">El Comité de Estándares de la Sociedad Española de Neonatología (SENeo) considera que el nuevo documento de la Academia Americana de Pediatría respecto a las recomendaciones del palivizumab para prevenir las infecciones graves por el virus respiratorio sincitial (VRS) no aporta nuevas evidencias científicas que justifiquen la modificación de las recomendaciones actuales de la SENeo. No obstante, se proponen unos ajustes en los criterios de las recomendaciones vigentes para reducir el coste del fármaco mediante su administración correcta y juiciosa.</p></span>" ] ] "NotaPie" => array:2 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Figueras Aloy J, Carbonell Estrany X, Comité de Estándares de la SENeo. Actualización de las recomendaciones de la Sociedad Española de Neonatología para la utilización del palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial. An Pediatr (Barc). 2015;82:199.e1–199.e2.</p>" ] 1 => array:3 [ "etiqueta" => "◊" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">The members of the Standards Committee of the SENeo are listed in <a class="elsevierStyleCrossRef" href="#sec0010">Appendix A</a>.</p>" "identificador" => "fn1" ] ] "apendice" => array:1 [ 0 => array:1 [ "seccion" => array:1 [ 0 => array:4 [ "apendice" => "<p id="par0040" class="elsevierStylePara elsevierViewall">Francesc Botet Mussons, Iñigo Echaniz Urcelay, José Ramón Fernández Lorenzo, Gloria Herranz Carrillo, Julio Moreno Hernando, Segundo Rite, Enrique Salguero, Manuel Sánchez Luna.</p>" "etiqueta" => "Appendix A" "titulo" => "Standards Committee of the SENeo" "identificador" => "sec0010" ] ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:3 [ 0 => array:3 [ "identificador" => "bib0020" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "Committee on Infectious Diseases and Bronchiolitis. Guidelines Committee" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1542/peds.2014-1665" "Revista" => array:7 [ "tituloSerie" => "Pediatrics" "fecha" => "2014" "volumen" => "134" "paginaInicial" => "415" "paginaFinal" => "420" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25070315" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0268960X12000732" "estado" => "S300" "issn" => "0268960X" ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0025" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recomendaciones para la prevención de la infección por virus respiratorio sincitial" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "Comisión de Estándares de la Sociedad Española de Neonatología" "etal" => false "autores" => array:2 [ 0 => "J. Figueras" 1 => "J. Quero" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "An Pediatr (Barc)" "fecha" => "2005" "volumen" => "63" "paginaInicial" => "357" "paginaFinal" => "362" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0030" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recomendaciones de uso del palivizumab para la prevención de la infección por VRS en el prematuro de 32,1 a 35,0 semanas de gestación" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "Comité de Estándares de la Sociedad Española de Neonatología" "etal" => false "autores" => array:2 [ 0 => "J. Figueras" 1 => "X. Carbonell" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "An Pediatr (Barc)" "fecha" => "2010" "volumen" => "73" "paginaInicial" => "1" "paginaFinal" => "4" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/23412879/0000008200000003/v2_201504151313/S234128791500037X/v2_201504151313/en/main.assets" "Apartado" => array:4 [ "identificador" => "33443" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Spanish Association of Paediatrics" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/23412879/0000008200000003/v2_201504151313/S234128791500037X/v2_201504151313/en/main.pdf?idApp=UINPBA00005H&text.app=https://analesdepediatria.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S234128791500037X?idApp=UINPBA00005H" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 10 | 10 | 20 |
| 2024 October | 48 | 31 | 79 |
| 2024 September | 62 | 33 | 95 |
| 2024 August | 49 | 57 | 106 |
| 2024 July | 51 | 26 | 77 |
| 2024 June | 60 | 24 | 84 |
| 2024 May | 48 | 31 | 79 |
| 2024 April | 61 | 45 | 106 |
| 2024 March | 44 | 23 | 67 |
| 2024 February | 44 | 26 | 70 |
| 2024 January | 40 | 28 | 68 |
| 2023 December | 41 | 13 | 54 |
| 2023 November | 50 | 34 | 84 |
| 2023 October | 42 | 28 | 70 |
| 2023 September | 39 | 21 | 60 |
| 2023 August | 31 | 12 | 43 |
| 2023 July | 37 | 34 | 71 |
| 2023 June | 41 | 33 | 74 |
| 2023 May | 42 | 30 | 72 |
| 2023 April | 47 | 16 | 63 |
| 2023 March | 61 | 30 | 91 |
| 2023 February | 64 | 20 | 84 |
| 2023 January | 49 | 40 | 89 |
| 2022 December | 58 | 35 | 93 |
| 2022 November | 78 | 41 | 119 |
| 2022 October | 72 | 69 | 141 |
| 2022 September | 55 | 43 | 98 |
| 2022 August | 101 | 59 | 160 |
| 2022 July | 67 | 46 | 113 |
| 2022 June | 60 | 49 | 109 |
| 2022 May | 45 | 38 | 83 |
| 2022 April | 47 | 53 | 100 |
| 2022 March | 72 | 41 | 113 |
| 2022 February | 79 | 28 | 107 |
| 2022 January | 55 | 46 | 101 |
| 2021 December | 50 | 44 | 94 |
| 2021 November | 58 | 56 | 114 |
| 2021 October | 69 | 69 | 138 |
| 2021 September | 61 | 50 | 111 |
| 2021 August | 74 | 43 | 117 |
| 2021 July | 95 | 44 | 139 |
| 2021 June | 53 | 38 | 91 |
| 2021 May | 45 | 36 | 81 |
| 2021 April | 110 | 105 | 215 |
| 2021 March | 113 | 38 | 151 |
| 2021 February | 68 | 29 | 97 |
| 2021 January | 61 | 38 | 99 |
| 2020 December | 54 | 45 | 99 |
| 2020 November | 60 | 22 | 82 |
| 2020 October | 68 | 18 | 86 |
| 2020 September | 63 | 21 | 84 |
| 2020 August | 51 | 18 | 69 |
| 2020 July | 44 | 18 | 62 |
| 2020 June | 59 | 11 | 70 |
| 2020 May | 46 | 34 | 80 |
| 2020 April | 35 | 17 | 52 |
| 2020 March | 47 | 30 | 77 |
| 2020 February | 44 | 16 | 60 |
| 2020 January | 36 | 13 | 49 |
| 2019 December | 51 | 27 | 78 |
| 2019 November | 37 | 22 | 59 |
| 2019 October | 53 | 19 | 72 |
| 2019 September | 45 | 22 | 67 |
| 2019 August | 48 | 20 | 68 |
| 2019 July | 58 | 40 | 98 |
| 2019 June | 61 | 17 | 78 |
| 2019 May | 102 | 45 | 147 |
| 2019 April | 140 | 39 | 179 |
| 2019 March | 49 | 17 | 66 |
| 2019 February | 45 | 23 | 68 |
| 2019 January | 56 | 16 | 72 |
| 2018 December | 53 | 34 | 87 |
| 2018 November | 65 | 34 | 99 |
| 2018 October | 79 | 18 | 97 |
| 2018 September | 43 | 22 | 65 |
| 2018 August | 3 | 0 | 3 |
| 2018 July | 3 | 0 | 3 |
| 2018 June | 2 | 0 | 2 |
| 2018 May | 6 | 0 | 6 |
| 2018 April | 32 | 0 | 32 |
| 2018 March | 45 | 0 | 45 |
| 2018 February | 16 | 0 | 16 |
| 2018 January | 19 | 0 | 19 |
| 2017 December | 21 | 0 | 21 |
| 2017 November | 37 | 0 | 37 |
| 2017 October | 25 | 0 | 25 |
| 2017 September | 32 | 0 | 32 |
| 2017 August | 21 | 0 | 21 |
| 2017 July | 27 | 2 | 29 |
| 2017 June | 36 | 13 | 49 |
| 2017 May | 36 | 8 | 44 |
| 2017 April | 41 | 7 | 48 |
| 2017 March | 17 | 8 | 25 |
| 2017 February | 11 | 8 | 19 |
| 2017 January | 26 | 8 | 34 |
| 2016 December | 52 | 4 | 56 |
| 2016 November | 62 | 10 | 72 |
| 2016 October | 56 | 14 | 70 |
| 2016 September | 64 | 11 | 75 |
| 2016 August | 38 | 7 | 45 |
| 2016 July | 28 | 18 | 46 |
Show all
